Login to Your Account



APG101 Works Better than Expected in Brain Cancer

By Nuala Moran
Staff Writer

Wednesday, August 1, 2012
LONDON – Apogenix GmbH announced better-than-expected results from the final analysis of its Phase II controlled study of APG101 in the second-line treatment of glioblastoma multiforme, reporting median progression-free survival of 19.7 weeks in the treated group compared to 10.8 weeks in the control arm.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription